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Laboratory data on at least three occasions revealed hypo-
phosphatemia associated with a marked decrease in the renal
tubular reabsorption of phosphate and a decrease in the renal
tubular transport maximum of phosphate (TmPi/GFR; Table 1).
His renal function has remained stable with a creatinine clear-
ance (GFR) of 102 mL/min. The decrease in TmPi/GFR occurred
in the presence of parathyroid hormone (PTH); PTH-related
peptide; 25(OH) vitamin D3; and 1,25-dihydroxy-vitamin D3
levels, all of which were within normal limits (Table 1). His
dietary history that was obtained by a renal dietitian revealed
adequate calcium and phosphorus intake of 1200 mg/day of
each. Bone mineral density measurement revealed osteopenia
of the lumbar spine.
The patient declined a bone biopsy. Treatment was initiated
with oral phosphate supplementation (Neutra Phos K powder),
1.25 g three times daily; 1,25-dihydroxy-vitamin D3 (Calcitriol),CASE PRESENTATION
0.25 mg 3 times daily, and skim milk, 1 cup three times daily.
A 59-year-old man was referred to the nephrology clinic There has been no immediate improvement in his serum phos-
at the Veterans Administration Medical Center at Dallas for phate level or the TmPi/GFR over a 3-month period.
evaluation and treatment of persistent post-transplant hypo-
phosphatemia.
The patient had developed end-stage renal disease that was DISCUSSION
presumed to be secondary to post-streptococcal glomerulone-
Dr. Moshe Levi (Chief of Nephrology, Dallas VAphritis. He had received a renal transplant 23 years ago from
Medical Center; and Professor of Medicine, The Univer-a living related donor. His maintenance regimen has comprised
sity of Texas Southwestern Medical Center; Dallas, Texas,prednisone, 10 mg/day, and azathioprine, 200 mg/day, and he
USA): Post-transplant hypophosphatemia, a commonhas had no episodes of rejection.
Several medical problems have occurred in the post-trans- disorder, is well described in the literature. Although
plant period, however. Recurrent atrial fibrillation has been described mainly in patients following renal transplanta-
treated with digoxin, 0.25 mg/day, and procainamide, 750 mg tion [1–12], post-transplant hypophosphatemia also oc-
every six hours. Moderate hypertension has been treated with a curs in patients undergoing bone marrow transplantationcalcium-channel blocker, felodipine, with good blood pressure
[13, 14]. In all reports, the decrease in serum inorganiccontrol (125/82 mm Hg). He has had osteopenia of the lumbar
phosphate (Pi) concentration was associated with an in-spine. Degenerative disease of the hips with joint space nar-
crease in urinary phosphate excretion and a significantrowing and lateral migration of both femoral heads necessi-
tated bilateral hip replacement. He has had benign prostatic decrease in the measured or derived ratio of maximal
hyperplasia, which has been treated with terazosin, 5 mg/day, rate of renal tubular transport of phosphate to glomeru-
and tamsulosin hydrocholoride, 0.4 mg/day. Microscopic hema- lar filtration rate (TmPi/GFR) [15]. In addition to the
turia prompted an intravenous pyelogram and cystoscopy; both impairment in renal tubular phosphate reabsorption, evi-
were normal. Finally, he has had persistent post-transplant
dence indicates that intestinal phosphate absorption ishypophosphatemia.
impaired in transplant patients [16, 17].
Regulation of serum phosphate concentration andThe Nephrology Forum is funded in part by grants from Amgen,
renal phosphate transportIncorporated; Merck & Co., Incorporated and Dialysis Clinic, Incorpo-
rated. Before considering the causes, consequences and treat-
ment of post-transplant hypophosphatemia, I plan toKey words: parathyroid hormone, vitamin D, glucocorticoids, cyclospo-
rine, phosphatonin, PHEX, stanniocalcin. briefly discuss the regulation of the serum phosphate
levels and renal phosphate transport. Major determi-Ó 2001 by the International Society of Nephrology
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Table 1. Serum and Urinary Biochemical Values
31 months ago 7 months ago 6 weeks ago Reference value
Serum
Creatinine mg/dL 1.2 1.2 1.1
Calcium mg/dL 9.2 9.6 9.0
Phosphate mg/dL 2.3 1.7 2.2
Alkaline phosphatase U/L 86 91 91
Intact PTH pg/mL 41 15 40 10–55 pg/mL
PTH-related peptide pmol/L — — ,0.2 ,2.0 pmol/L
25-OH vitamin D3 ng/ml 37 24 36 9–52 ng/mL
1,25 (OH)2 vitamin D3 pg/mL 41 52 43 15–60 pg/mL
Ionized calcium mmol/L — 1.30 —
Urine
Phosphate mg/dL 38.5 32.5 32.6
Creatinine mg/dL 76.6 60.2 50.1
Cyclic AMP nmol/dL — 2.6 —
Phosphate transport
FEPi % 26.1 38.1 32.5
TmPi/GFR mg/100 mL 1.9 1.1 1.5 2.5–4.2 mg/dL
Abbreviations are: PTH, parathyroid hormone; AMP, adenosine monophosphate.
Fig. 1. Major determinants of extracellular
matrix (ECF) or serum inorganic phosphate
(Pi) concentration. They include dietary Pi
intake, intestinal Pi absorption, urinary Pi ex-
cretion and shift into the cells. With permis-
sion from Levi M, Popovtzer M: Disorders of
Phosphate Balance, in Atlas of Diseases of the
Kidney (vol 1), edited by Schrier RW, Berl T,
Bonventre JV, pp 7.1–7.14, 1999
nants of phosphate concentration are dietary phosphate level of the proximal tubular BBM Na/Pi cotransport
system [18, 19]. The factors that regulate renal proximalintake, gastrointestinal phosphate absorption, shifts be-
tween the intracellular and extracellular spaces, and re- tubular phosphate reabsorption are listed in Table 2.
To date, three families of Na/Pi cotransporters havenal tubular phosphate reabsorption (Fig. 1). Under
steady-state conditions, the kidney plays the major role been identified and cloned in mammalian kidney (Fig. 3)
[20–22]. The type I (Npt1) and type II (Npt2) cotrans-in regulating phosphate homeostasis (Fig. 2).
Our patient with sustained post-transplant hypophos- porters, expressed predominantly in the kidney, have been
localized to the apical BBM of the proximal tubule. Thephatemia had definite evidence of impaired renal phos-
phate transport because the TmPi/GFR was significantly type III cotransporters (Glvr-1 and Ram-1), retroviral
receptors that are ubiquitously expressed, might serve asdecreased. This patient’s average TmPi/GFR was 1.5 mg/
100 mL compared to a normal range of 2.5 to 4.2 mg/ housekeeping Na/Pi cotransporters. Experimental data
suggest that the type IIa renal apical BBM Na/Pi cotrans-100 mL.
Phosphate essentially is freely filtered across the glo- port system is the isoform that mediates the majority of
renal proximal tubule phosphate transport. RNase H-merulus, and most of the phosphate is reabsorbed along
the proximal tubule via a sodium gradient-dependent mediated hybrid depletion analysis indicates that type I
or type III Na/Pi cotransporters contribute little to Na/Piprocess (Na/Pi cotransport). The Na/Pi cotransporter is
located on the apical brush border membrane (BBM) cotransport in the mouse renal cortex [23]. In fact, Npt1,
Npt2, Glvr-1, and Ram-1 account for approximately 15%,of the proximal tubule. Evidence to date indicates that
regulation of overall renal tubular phosphate transport 84%, 0.5%, and 0.5%, respectively, of total Na/Pi co-
transporter mRNA in murine kidney [24]. More recently,by dietary, hormonal, or metabolic factors occurs at the
Nephrology Forum: Post-transplant hypophosphatemia 2379
Fig. 2. Summary of phosphate metabolism for a normal adult in neutral phosphate balance. Approximately 1400 mg of phosphate is ingested
daily, 490 mg of which is excreted in the stool and 910 mg in the urine. The kidney, gastrointestinal (GI) tract, and bone are the major organs
involved in phosphorous homeostasis. With permission from Levi M, Popovtzer M: Disorders of Phosphate Balance, in Atlas of Diseases of the
Kidney (vol 1), editged by Schrier RW, Berl T, Bonventre JV, pp 7.1–7.14, 1999.
targeted inactivation of the type IIa Na/Pi cotransporter glucocorticoids, thyroid hormone, and the develop-
mental/aging process is mediated by alterations in thein mice (Npt22/2 mice) caused hypophosphatemia and
increased urinary phosphate excretion. Transport studies abundance of the apical membrane type IIa Na/Pi co-
transport protein (Fig. 4) [26–31]. Although we lackin BBM estimated that the type IIa transporter mediates
at least 85% of proximal tubular Na/Pi cotransport [24]. definite evidence, I believe that the impairment in renal
tubular phosphate transport in our patient, resulting inIn addition, Npt22/2 mice are unable to adapt to dietary
phosphate deprivation; this finding indicates that Npt2 significant and sustained urinary phosphate excretion
and hypophosphatemia, was secondary to impaired ex-is essential for the adaptive BBM Na/Pi cotransport re-
sponse to phosphate deprivation [25]. In fact, the regula- pression of the proximal tubular BBM type IIa Na/Pi
cotransport protein.tion of Na/Pi cotransport by dietary phosphate, PTH,
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Table 2. Factors regulating renal proximal tubular 1,25(OH)2D3 improves the TmPi/GFR [8, 11, 12]. Somephosphate reabsorption
patients, however, either have no evidence of increased
Decreased transport Increased transport PTH levels, or the decrease in TmPi/GFR is independent
High-phosphate diet Low-phosphate diet of PTH activity [5–8]. This is definitely the case in today’sPTH excess PTH deficiency
patient, as he had normal PTH levels and PTH activity,PTH-related peptide Insulin
Glucocorticoids Thyroid hormone the latter determined by normal urinary cAMP levels.
Chronic metabolic acidosis 1,25 dihydroxy-vitamin D3 1,25(OH)2 vitamin D3. This major vitamin D metabo-Calcitonin Growth hormone
lite is an important regulator of intestinal and renal tubularStanniocalcin-2 High-calcium diet
Phosphatonin Stanniocalcin-1 phosphate transport. Treatment of rats with 1,25(OH)2D3
Aging stimulates BBM Na/Pi cotransport [36]. Also, 1,25(OH)2D3Atrial natriuretic peptide
stimulates Na/Pi cotransport in isolated chicken renal tu-Fasting
Hypokalemia bular preparations [37] and in a subclone of opossum kid-
Hypercalcemia ney (OK) cells [38]. Furthermore, recent studies have iden-Diuretics
tified a vitamin D-responsive element in the human Npt-2
PTH is parathyroid hormone.
gene [39]. In the upper small intestine, 1,25(OH)2D3
also stimulates BBM Na/Pi cotransport activity [40]. Al-
though it has not yet been directly proven, the stimula-
tory effect of 1,25(OH)2D3 presumably is mediatedPotential mediators of
through stimulation of the intestinal type IIb Na/Pi co-post-transplant hypophosphatemia
transport protein [41].The factors that could mediate impairment in renal
Levels of 1,25(OH)2D3 are low in patients with chronictubular phosphate reabsorption and/or intestinal phos-
renal failure and ESRD. Although levels of 1,25(OH)2D3phate absorption in transplant patients include (1) in-
usually revert to normal rapidly after successful renalcreased parathyroid hormone level and activity; (2) rela-
transplantation [33–35], some patients still can have rela-tive deficiency of 1,25(OH)2D3; (3) glucocorticoids; (4) tively low levels that can play a role in impaired intestinalimmunosuppressive drugs, including cyclosporine; (5)
phosphate absorption and renal tubular phosphate reab-phosphatonin and/or PHEX, a phosphate-regulating gene
sorption. Today’s patient had “normal” 25-OH andwith homologies to endopeptidases located on the X
1,25(OH)2D3 levels (Table 1). Nevertheless I would ar-chromosome; and (6) stanniocalcin.
gue that these levels are relatively low, given the low
Parathyroid hormone. Parathyroid hormone (PTH) serum phosphate concentration. Treatment of the patient
has been known for decades to be an important regulator with 1,25(OH)2D3 failed to normalize the serum phos-of phosphate reabsorption by the kidney. Parathyroidec- phate concentration, however.
tomy decreases urinary phosphate excretion, whereas in- Glucocorticoids. Glucocorticoids are important regu-
fusion of PTH increases phosphate excretion. Parathyroid lators of renal phosphate transport. It is well known
hormone activates a number of signaling pathways, in- that glucocorticoid excess (Cushing’s disease) and the
cluding adenylyl cyclase and protein kinase A, and phos- administration of glucocorticoids to humans or experi-
pholipase C and protein kinase C [19]. The phosphaturic mental animals decrease tubular reabsorption of phos-
action of PTH ultimately is due to inhibition of proximal phate. In contrast, glucocorticoid deficiency after adrena-
tubular BBM Na/Pi cotransport activity as a result of lectomy increases tubular reabsorption of phosphate.
decreased expression of BBM type IIa Na/Pi cotransport The primary site of action of glucocorticoids where renal
protein (Fig. 4) [31]. This sequence is caused by post- phosphate reabsorption is reduced is the proximal tubule
transcriptional mechanisms that include rapid endocyto- [42]. The inhibition of phosphate reabsorption by gluco-
sis of the protein from the apical membrane and delivery corticoids is independent of parathyroid hormone activ-
to the lysosomes for eventual degradation [31]. ity. The inhibitory effect of glucocorticoids on renal tubu-
In some patients with post-transplant hypophospha- lar phosphate transport, expressed at the level of the
temia, evidence suggests that increased PTH levels proximal tubular brush border membrane, is mediated
and/or activity play a role in the decrease in TmPi/GFR by decreased expression of the type IIa Na/Pi cotransport
[4, 5, 7, 8, 11, 12]. Obviously, PTH levels are very high protein [26, 43]. Glucocorticoids have a direct and selec-
in patients with chronic renal failure or end-stage renal tive inhibitory effect on Na/Pi cotransport activity in
disease (ESRD). Although PTH levels usually decline isolated proximal tubular cells, primary cultured renal
rapidly after renal transplantation, some patients with cells, and OK cells. Glucocorticoids also inhibit intestinal
severe hyperparathyroidism continue to have high levels BBM Na/Pi cotransport activity [17, 44]. Today’s patient
of PTH [32–35]. In fact, these patients have an inverse had taken glucocorticoids for more than two decades, and
relationship between PTH levels and TmPi/GFR. In ad- it is likely that the glucocorticoids are playing a significant
role in his impaired TmPi/GFR and osteopenia.dition, inhibition of PTH levels by calcium and/or
Nephrology Forum: Post-transplant hypophosphatemia 2381
Fig. 3. Sodium gradient-dependent phosphate
(Na/Pi) cotransporter proteins in the renal
proximal tubule. With permission from: Murer
H, Forster I, Hernando N, Lambert G, Trae-
bert M, Biber J: Posttranscriptional regulation
of the proximal tubule NaPi-II transporter in
response to PTH and dietary Pi. Am J Physiol
277:F676-F684, 1999
Fig. 4. Regulation of renal proximal tubular
Na/Pi cotransporter activity is mediated via
endocytosis and/or exocytosis of the type II
Na/Pi cotransporter protein from and to the
apical plasma membrane. Adapted from:
Murer H, Forster I, Hernando N, Lambert
G, Traebert M, Biber J: Posttranscriptional
regulation of the proximal tubule NaPi-II
transporter in response to PTH and dietary
Pi. Am J Physiol 277:F676-F684, 1999
Cyclosporine. Cyclosporine has well-recognized renal cyclosporine, TmPi/GFR remains unchanged [46]. It is
possible that in renal transplant patients, cyclosporinetubular effects, including modulating potassium excre-
tion and magnesium reabsorption, but its effect on renal modulates renal Na/Pi cotransport activity. This patient,
however, had not been taking cyclosporine.tubular phosphate transport is not known. In the rat,
cyclosporine inhibits BBM Na/Pi cotransport activity [45]. Phosphatonin and PHEX. Studies in patients with tu-
mor-induced osteomalacia and hypophosphatemia, im-But in patients with autoimmune uveitis treated with
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paired TmPi/GFR, and low 1,25(OH)2D3 levels suggested Stanniocalcin. A glycohormone that plays a major
role in the calcium and phosphate homeostasis of fish,the presence of a humoral factor distinct from parathyroid
hormone-related peptide [47]. This as-yet-unidentified stanniocalcin is produced in the corpuscles of Stannius,
which are specialized endocrine organs that are closelyfactor, derived from tumors of patients with oncogenic
osteomalacia, is called phosphatonin [48]. Phosphatonin associated with the kidneys of teleost fish. High levels
of serum calcium stimulate the release of stanniocalcininhibits Na/Pi cotransport activity in mice [49] and in OK
cells [50, 51] independent of changes in cellular cAMP into the circulation. Stanniocalcin inhibits calcium up-
take by the gills and gut and stimulates phosphate reab-content.
The clinical picture in tumor-induced osteomalacia is sorption by the kidney [61].
In situ hybridization and immunocytochemical studiesquite similar to that of X-linked hypophosphatemia.
X-linked hypophosphatemia, an X-linked dominant dis- have shown that stanniocalcin is expressed in the human,
mouse, and rat kidney and in MDCK cells [62]. Stannio-order with complete penetrance, is a renal tubular abnor-
mality that results in impaired TmPi/GFR, hypophos- calcin is synthesized in the mammalian kidney and acts
in an autocrine and paracrine fashion to regulate calciumphatemia, and impaired 1,25(OH)2D3 levels. The study
of the detailed molecular and cellular mechanisms of and phosphate metabolism.
Two mammalian homologues of stanniocalcin have beenthis genetic disorder has been made possible by the exis-
tence of an animal model, the Hyp mouse. Extensive identified, stanniocalcin 1 and stanniocalcin 2 [63, 64].
These two isoforms of stanniocalcin have seemingly op-studies in X-linked hypophosphatemia [52] and the Hyp
mouse [53–55] indicate that the defect in renal phosphate posing effects on renal phosphate transport. Stanniocal-
cin 1 stimulates intestinal and renal phosphate transporttransport is secondary to the effects of a circulating hor-
mone or metabolic factor. Hyp mouse osteoblasts pro- in the rat [65, 66]. In contrast, stanniocalcin 2 inhibits
Na/Pi cotransport in OK cells [63]. At present, we do notduce a phosphaturic factor that acts like phosphatonin
[53]. This finding of a bone-derived factor (phospha- understand the effects of stanniocalcin in the mammalian
kidney, nor do we know what role stanniocalcin playstonin) that impairs renal phosphate transport is intri-
guing, as the Hyp mouse osteoblasts have defective bone in post-transplant hypophosphatemia.
formation and mineralization [56]. Therefore it seems
Consequencesthat a similar factor, phosphatonin or phosphatonins,
mediates the impaired renal phosphate transport in both The major consequence of post-transplant hypophos-
phatemia is a significant and progressive decrease in bonetumor-induced osteomalacia and X-linked hypophos-
phatemia. mineral density (osteopenia) [67–71]. Transplant-associ-
ated bone loss is most rapid in the first 6 to 12 monthsRecently PHEX was identified via positional cloning
as the gene defective in X-linked hypophosphatemia and after transplantation, for example, at a rate of 3% to
8% bone density decrease of the lumbar spine. Rapidthe Hyp mouse [57]. PHEX expression is high in bone
and in tumor tissue associated with tumor-induced osteo- bone loss during the first year after transplantation also
occurs in a gender-dependent fashion, with women losingmalacia [58]. Additional investigations have established
that deactivating mutations of the PHEX gene underlie bone mainly from the lumbar spine and men from the
femoral neck.the phenotypic expression of X-linked hypophosphate-
mia [59]. The facts that PHEX is expressed highly in bone Major clinical complications of the decrease in bone
mineral density include spontaneous fractures and avas-and that phosphatonin or a phosphatonin-like substance
also might originate in the bone have led to possible cular bone necrosis [72–74]. The incidence of fractures
is approximately 2% per year in nondiabetic patients,explanations for how interactions between PHEX and
phosphatonin play a critical role in the pathophysiology 5% per year in diabetic patients, and as much as 10%
per year in kidney and pancreas transplant patients. Inof X-linked hypophosphatemia and tumor-induced os-
teomalacia. In the presence of PHEX mutations, there addition to increased risk for fractures, progressive bone
compression of the osteopenic bones and ischemia alsocan be increased levels of phosphatonin that result in
impaired renal proximal tubular Na/Pi cotransport [55]. can result in avascular necrosis.
Bone histology analysis demonstrates low-turnover os-It is not known whether patients with post-transplant
hypophosphatemia have mutations of the PHEX gene. teopenia [67], a decrease in trabecular bone volume [68],
and sometimes even osteomalacia [75]. The osteopeniaA recent preliminary study demonstrated, however, that
serum from patients with hypophosphatemia and im- is most likely caused by a combination of several ongoing
processes, including pre-transplant osteodystrophy, post-paired TmPi/GFR soon after transplant does inhibit OK
cell Na/Pi cotransport activity [60]. Therefore, post- transplant glucocorticoid-induced decreased bone forma-
tion, hypophosphatemic osteomalacia, and cyclosporine.transplant patients also might have a phosphatonin-like
substance that mediates the impairment in renal phos- Glucocorticoids have direct and indirect effects on bone
mineralization. Glucocorticoids directly inhibit osteo-phate transport and osteopenia.
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blastogenesis and promote apoptosis of osteoblasts and Dr. Levi: Several investigators have tried to establish
a correlation between hypophosphatemia and the pres-osteocytes [76]. Glucocorticoids also inhibit intestinal
calcium and phosphate absorption, induce mild second- ence of ATN or rejection. In the presence of rejection,
there can be proximal tubular injury. Also, you would beary hyperparathyroidism, and inhibit the secretion of sex
hormones. Cyclosporine modulates bone mineralization using higher doses of immunosuppressive medications,
which could inhibit renal and/or gastrointestinal phos-in vivo and in vitro [77]. In addition, phosphatonin-like
agents also can impair bone mineralization. phate transport. In the presence of ATN, proximal tubu-
lar injury results in the functional impairment of a num-
Treatment ber of transport processes including sodium/hydrogen
exchange and sodium/phosphate cotransport. HoweverTreatment for post-transplant hypophosphatemia in-
cludes oral phosphorus replacement, calcium supple- the majority of the patients, including today’s patient,
develop hypophosphatemia in the absence of any evi-ments, and 1,25(OH)2 vitamin D3 or 1(OH) vitamin D3.
These agents are successful in restoring adequate calcium dence of rejection or post-transplant ATN.
Dr. Madias: In living related transplantation, haveand phosphorus balance in some but not all patients
[78]. The efficacy of these treatment modalities on bone any studies compared renal phosphate handling between
hypophosphatemic recipients and the uninephrectom-histology and densitometry and on complications such
as fracture rate has not been determined. ized donors?
Dr. Levi: I am aware of at least one study that usedRecently bisphosphonates have been emphasized as
additional therapy for prevention of post-transplant the donors as controls. The donors did not have a defect
in phosphate transport.bone loss. A recent study showed that the early rapid
bone loss that occurs during the first year after renal Dr. Andrew J. King (Division of Nephrology, New
England Medical Center, Boston, Massachusetts): On atransplantation is prevented by pamidronate [79]. The
long-term effects and efficacy of bisphosphonates are practical level, when we replete these patients with phos-
phate, do you have any recommendations regarding thenot known, so therapy with bisphosphonates should be
specific preparation or method of administering the oralconsidered only for high-risk patients [80].
phosphate supplement?
Dr. Levi: In the patients with post-transplant hypo-
QUESTIONS AND ANSWERS phosphatemia, the best method of replacing phosphate
Dr. Nicolaos E. Madias (Executive Academic Dean, is giving Neutra-Phos orally. Each package contains ap-
Tufts University School of Medicine, Boston, Massachu- proximately 250 mg of phosphorus. We give one package
setts): As a group, do patients with post-transplant hypo- 3 times daily with meals and adjust the dosage according
phosphatemia have more severe secondary/tertiary hy- to the serum phosphate concentration. In the immediate
perparathyroidism than nonhypophosphatemic patients? post-transplant period, there is evidence of mild renal
Dr. Levi: There is definitely a subset of hypophos- tubular acidosis, and replacement with Neutra-Phos also
phatemic patients who have evidence of increased PTH improves urinary acid excretion. An alternative method
levels and/or increased PTH activity. In these patients, of replacing phosphorus is asking the patient to drink
if you inhibit PTH by giving intravenous calcium or oral fat-free milk, usually at least three 8 ounce glasses a day.
calcium with vitamin D, renal phosphate transport in- Dr. King: What is the target level for the serum phos-
creases and the hypophosphatemia improves. The rest phate?
of the hypophosphatemic patients show no evidence of Dr. Levi: The initial serum target level should be at
increased PTH levels or activity, and the hypophosphate- least 2.5 mg/dL. However, one needs to be careful not
mia is independent of PTH. In fact, in our patient the to exceed 4.5 mg/dL to avoid secondary hyperparathy-
reasoning behind placing him on calcium and calcitriol roidism.
was to determine whether we could normalize his serum Dr. John T. Harrington (Dean, Tufts University
phosphorus level in part by inhibiting PTH activity. Our School of Medicine): In patients who have not had or
patient, however, did not have increased PTH levels who refuse bone biopsy, what surrogate, noninvasive test
or evidence of increased PTH activity (normal urinary is available? Would muscle biopsy and measurement of
cAMP) and did not respond to calcium and vitamin D. tissue phosphate be of any value?
Thus, his hypophosphatemia is mediated by PTH-inde- Dr. Levi: There is really no good substitute for bone
pendent mechanisms. biopsy. Muscle biopsy and tissue phosphate level would
Dr. Madias: Compared with non-hypophosphatemic only be useful in determining whether a true phosphorus
patients, are patients with post-transplant hypophospha- deficiency exists. Alternatively, if one wishes to examine
temia characterized by a greater incidence of acute tubu- any of the consequences of the hypophosphatemia, I
lar necrosis or episodes of rejection? Do these patients think that the best noninvasive test is an NMR with
appropriate age- and gender-matched controls. Bonefeature other renal transport abnormalities?
Nephrology Forum: Post-transplant hypophosphatemia2384
biopsy and bone histomorphometry, on the other hand, Dr. Levi: I am not aware of any studies using calcimi-
metic agents in patients with post-transplant hypophos-are very important in determining the cause of the bone
disease and the physiologic processes that are operating phatemia.
Dr. Harrington: What are the risks and benefits ofat the level of the bone. This is especially important
in view of several studies now examining the role of bisphosphonates?
Dr. Levi: Bisphosphonates are pyrophosphate ana-bisphosphonates in the treatment of post-transplant os-
teopenia. I don’t believe that bone mineral density mea- logues that reduce bone resorption. They work great in
the case of postmenopausal osteoporosis, since estrogensurements alone will be sufficient to evaluate the effec-
tiveness of most therapies, including bisphosphonates. deficiency in postmenopausal women is associated with
increased osteoclast activation and accelerated bone re-The reason for performing a bone biopsy is to determine
the cause of the osteopenia. In the presence of osteoma- sorption. In contrast, renal transplant patients usually
have a low-turnover bone lesion that resembles ady-lacia, one can be aggressive with phosphorus replace-
ment and 1,25(OH)2 vitamin D3 therapy. However, if the namic bone disease. In these patients therefore the long-
term consequences of bisphosphonates are of concern.patient has low turnover or adynamic bone disease, one
has to be careful not to suppress PTH levels and thus Although, as I mentioned, a recent study did show that
treatment of renal transplant patients with pamidronateconsider alternative therapies.
Dr. Harrington: You mentioned that the type IIa prevented the decline in bone density, the study did not
determine the effect of the treatment on bone histomor-sodium-phosphorus transporter is the important one in
mediating renal tubular phosphate transport. From what phometry or on the incidence of fractures. At this time,
treatment with bisphophonates should be offered onlyyou’ve said, I assume that the transporter is similar in
the renal tubular cell and bone cell. Is that true? If so, to very high-risk patients. In addition to bone density
measurements in these patients, we need to obtain fol-could you tell us some details about the similarity be-
tween those two transport systems? low-up bone biopsies to determine bone histomorpho-
metry.Dr. Levi: We know that the bone cells, including osteo-
blasts and osteoclasts, have a sodium-dependent phos- Dr. Dana Miskulin (Renal Fellow, Division of Ne-
phrology, New England Medical Center): Is the use ofphate transporter system that is also regulated by PTH,
vitamin D, glucocorticoids, and pH. However, the full vitamin D in a patient who had normal vitamin D and
PTH levels a rational approach?identity of the one or more bone phosphate transporters
is not known yet. Dr. Levi: That is a very good question. We discussed
this issue in detail prior to initiating the vitamin D andDr. Harrington: Is the same transporter present in
any other cells? calcium therapy. Let me emphasize that the vitamin D
levels in our patient are within a normal range, but in theDr. Levi: The type IIa phosphate transport protein
also has been identified in lung cells. In addition, we have presence of hypophosphatemia they are inappropriately
normal. Vitamin D levels should be high. We havepreliminary evidence that the transporter is expressed in
the brain, where it is also regulated by dietary phosphate. started vitamin D therapy to increase phosphorus reab-
sorption in the gastrointestinal tract and also to possiblyDr. Ronald D. Perrone (Division of Nephrology,
New England Medical Center): I have a question about improve renal tubular phosphate transport. In this pa-
tient, however, so far vitamin D has not been able tothe mechanism of glucocorticoid-induced hypophospha-
temia. Are there any systematic studies of this phenome- fully restore normal serum phosphate levels. Maybe
higher doses of vitamin D are needed. One has to care-non in other groups of patients who take glucocorticoids
indefinitely, for example, asthmatics or other patients fully titrate the vitamin D doses with frequent monitor-
ing of serum calcium and phosphorus levels to avoidwithout renal dysfunction or hyperparathyroidism?
Dr. Levi: Long-term use of high dose glucocorticoids vitamin D toxicity.
Dr. Madias: Are hypercalciuria and nephrolithiasishas been repeatedly shown to cause or be associated
with phosphaturia and negative phosphate balance. This concerns in patients with post-transplant hypophospha-
temia, especially those without hyperparathyroidism?is of special importance to patients with asthma, espe-
cially when they present with respiratory distress, as the Dr. Levi: Yes, they are of concern, especially during
calcium and vitamin D therapy, and the patients haveassociated hyperventilation and respiratory alkalosis re-
sult in further hypophosphatemia due to an intracellular to be carefully monitored.
Dr. Harrington: I’ve always been interested in com-shift of phosphate. The hypophosphatemia can then re-
sult in respiratory muscle weakness, which is of major parative physiology. Could you expand on the story of
how the transporter jumped from fish to humans?concern to asthmatic patients.
Dr. Madias: Is there any experience with using calci- Dr. Levi: Since phosphate transport is essential for all
organisms and cells, it is not surprising that fish andmimetic agents in the management of post-transplant
hypophosphatemia? humans have the transporter. However, I am not sure I
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mineral metabolism after successful renal transplantation. Minercan answer the question as to how the phosphate trans-
Electrolyte Metab 11:167–172, 1985
porter and regulatory hormones, such as stanniocalcin 10. Parfitt AM, Kleerekoper M, Cruz C: Reduced phosphate reab-
sorption unrelated to parathyroid hormone after renal transplanta-(which also was first reported to be present in fish),
tion: Implications for the pathogenesis of hyperparathyroidism injumped from fish to humans.
chronic renal failure. Miner Electrolyte Metab 12:356–362, 1986
Dr. Madias: What do we know about the features 11. Pabico RC, McKenna BA, the Renal Transplant Team: Meta-
bolic problems in renal transplant patients: Persistent hyperpara-and function of non-type II phosphate transporters?
thyroidism and hypophosphatemia: Effects of intravenous calciumDr. Levi: At this time the contribution of the type I
infusion. Transplant Proc 20:438–442, 1988
phosphate transporter and type III phosphate trans- 12. Steiner RW, Ziegler M, Halasz NA, et al: Effect of daily oral
vitamin D and calcium therapy, hypophosphatemia, and endoge-porter to the overall regulation of renal phosphate trans-
nous 1-25 dihydroxycholecalciferol on parathyroid hormone andport is not clear. Type I phosphate transporter mediates phosphate wasting in renal transplant recipients. Transplantation
almost 15% of renal phosphate transport; however, it is 56:843–846, 1993
13. Raanani P, Berkowicz M, Harden I, Ben-Bassat I: Severe hypo-not regulated by dietary phosphate, parathyroid hor-
phosphataemia in autograft recipients during accelerated leucocytemone, or glucocorticoids. In addition, when the type II recovery. Br J Haematol 91:1031–1032, 1995
phosphate transporter knockout mice (Npt22/2 mice) 14. Crook M, Swaminathan R, Schey S: Hypophosphataemia in pa-
tients undergoing bone marrow transplantation. Leuk Lymphomaare fed a low-phosphate diet, neither the type I phos-
22:335–337, 1996
phate transporter nor the type III phosphate transporter 15. Walton RJ, Bijvoet OLM: Nomogram for derivation of renal
threshold phosphate concentration. Lancet 2:309–310, 1975can protect the animal against phosphaturia and hypo-
16. Farrington K, Varghese Z, Newman SP, et al: Dissociation ofphosphatemia.
absorptions of calcium and phosphate after successful cadaveric
renal transplantation. Br Med J 1:712–714, 1979
17. Rosental R, Babarykin D, Fomina O, et al: HypophosphatemiaACKNOWLEDGMENTS
after successful transplantation of the kidney: Clinico-experimental
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by grant support from the Department of Veteran Affairs Research phosphate reabsorption: Molecular mechanisms. Physiol Rev
Service (Merit Review) and the National Institutes of Health. The 8:1373–1409, 2000
author thanks Teresa Autrey for secretarial assistance and the Library 20. Magagnin S, Werner A, Markovich D, et al: Expression cloning
Service and Medical Media Departments at the Dallas VA for literature of human and rat renal cortex Na/Pi cotransport. Proc Natl Acad
search and illustrations. Sci USA 90:5979–5983, 1993
21. Kavanaugh MP, Miller DG, Zhang W, et al: Cell-surface recep-
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